全球年度药王尘埃落定。 2月4日，礼来发布的2025年财报显示，公司的"明星单品"替尔泊肽降糖适应证产品Mounjaro全年销售额 达229.65亿美元，同比增长99%，持续抢占全球糖尿病用药市场份额；减重适应证产品Zepbound全年销 售额135.42亿美元，同比增长175%。 这两个适应证合计起来，替尔泊肽2025年全年销售额365.07亿美元（折合人民币2534.24亿元），超过诺 和诺德司美格鲁肽2025年销售额（361亿美元），成为2025年全球销售额最大的药品。 回顾GLP-1赛道，诺和诺德司美格鲁肽在减肥药适应证上的开发成功，带火了整个GLP-1赛道开发火 热。作为GLP-1/GIP双靶点药物的替尔泊肽，虽然后来居上，但相比司美格鲁肽是GLP-1单靶点药物， 展现出更优的减重效果。 司美格鲁肽减肥适应证在全球上市后，曾一度受制于产能供应紧张挑战。而礼来的替尔泊肽的开发到生 产，背后有中国企业赋能身影。 有分析指出，礼来在应对GLP-1类药物（如替尔泊肽）巨大的市场需求时，采取了"内部扩产+外部合 作"的策略。作为医药外包公司，中国企业药明康德在全球多肽和寡核苷酸（TIDES）领域产能占据优 势 ...

Core Viewpoint - The innovative drug ETF Tianhong (517380) has shown strong performance, with significant inflows and positive market reactions to earnings reports from key companies in the sector, particularly Eli Lilly's impressive revenue growth driven by weight loss drugs [2][3]. Group 1: ETF Performance - As of February 5, 2026, the innovative drug ETF Tianhong (517380) recorded a transaction volume of 4.9451 million yuan, with the tracked index HSSSHID rising by 0.11% [1]. - Over the past 20 trading days, the innovative drug ETF Tianhong (517380) attracted a total of 395 million yuan [2]. Group 2: Company Highlights - Eli Lilly reported a 43% year-over-year increase in Q4 revenue, reaching 19.29 billion dollars, with adjusted earnings per share of 7.54 dollars, both exceeding market expectations [2]. - Eli Lilly's weight loss drugs, Mounjaro and Zepbound, generated over 11.6 billion dollars in sales, accounting for more than 60% of total revenue [2]. - The company projects full-year revenue for 2026 to be between 80 billion and 83 billion dollars, with adjusted earnings per share expected to be between 33.50 and 35 dollars, also surpassing market forecasts [2]. Group 3: Industry Insights - Donghai Securities anticipates that the innovative drug sector will enter a phase of accelerated profit realization by 2025, with companies like Nocare and Rongchang Biopharma turning profitable [3]. - The core drivers of this growth are rapid commercialization of products and business development (BD) collaborations, with companies leveraging both to enhance profitability [3]. - The strong performance of the innovative drug sector validates the effectiveness of the domestic innovative drug business model, with core product commercialization supported by healthcare insurance being a fundamental growth driver [3].

2026 年 2 月 5 日 星期四 昨日港股窄幅波动。恒生指数及国企指数分别收报 26,847 点及 9,048 点，前者上升 0.1%，后者下跌 0.1%。港股成交合共 2,854 亿港元，较前日的 3,352 亿港元，下跌 14.9%，或反映投资者观望情绪增加。分类指数方面，能源、地产建筑、原 材料业指数分别上升 3.0%、2.1%、1.4%；资讯科技、非必需性消费则分别下跌 3.4%、0.4%。蓝筹个股方面，信义玻璃 (868 HK)及中国神华(1088 HK)领涨，分别上升 5.9%及 5.7%；携程集团(9961 HK)及腾讯控股(700 HK)领跌，分别下跌 6.1%及 4.0%。 主要内房港股明显上升，例如华润置地(1109 HK)、中国海外发展(688 HK)、越秀地产(123 HK)、万科企业(2202 HK)上涨 3.9%-6.2%。近期部分投资机构预期政府在短中期未来将公布更积极推动房地产政策。至目前为止,房地产销售数字仍需 突围，存销比率也较高。我们盼望推动政策的力度可较大。 ➢ 每日大市点评 昨晚美股表现分化，科技股受到抛售，例如 AMD(AMD US)下跌 17.3%，光伏股则上 ...

截至2026年2月5日 09:41，中证港股通医药卫生综合指数(930965)上涨0.32%，成分股银诺医药-B上涨 10.07%，药明康德上涨2.73%，海吉亚医疗上涨2.65%，再鼎医药上涨2.13%，四环医药上涨1.89%。港 股医药ETF(159718)下跌0.22%，最新报价0.92元。 消息面上，政策持续支持医药产业，国家药监局称，"十五五"期间将大力支持生物制造产业创新发展。 港股医药ETF紧密跟踪中证港股通医药卫生综合指数，中证港股通医药卫生综合指数从港股通范围内选 取50只流动性较好、市值较大的医疗卫生行业上市公司证券作为指数样本，以反映港股通范围内医药卫 生上市公司证券的整体表现。 数据显示，截至2026年1月30日，中证港股通医药卫生综合指数(930965)前十大权重股分别为药明生 物、百济神州、信达生物、康方生物、京东健康、石药集团、中国生物制药、翰森制药、药明康德、三 生制药，前十大权重股合计占比64.57%。 港股医药ETF(159718)，场外联接(平安中证港股医药ETF联接A：019598；平安中证港股医药ETF联接 C：019599；平安中证港股医药ETF联接E：024544 ...

信达生物2月4日公布其2025全年业绩，总产品收入约人民币119亿元，同比保持约45%的强劲增长态 势。2025年Q4，信达生物有6款新药纳入2026年国家医保目录。 东海证券表示，2025年创新药板块进入盈利兑现提速期，诺诚健华、荣昌生物等实现扭亏为盈，三生国 健等业绩大幅预增，君实生物等显著减亏，核心驱动主要来自商业化产品快速放量和BD合作两大主 线。 2月5日早盘，港股市场主要指数集体下挫，聚焦创新药、AI医疗主线的港股通医疗ETF(520510)一度逆 势翻红，脑动极光、药明康德（603259）、凯莱英（002821）等持仓股涨幅靠前。 ...

Group 1 - The stock market style may be changing, with a notable adjustment in US tech stocks, including Oracle's price dropping nearly 60% from its peak and SNDK experiencing a significant decline [1] - A-shares may see a shift in style, with banks and dividend stocks potentially outperforming, leading to a focus on quality banks such as Jiangsu Bank, Nanjing Bank, Hangzhou Bank, Ningbo Bank, and China Merchants Bank for potential gains [1] - As of February 4, 2026, the Shanghai 180 Index (000010) rose by 1.01%, with component stocks like JinkoSolar up 20.00%, Yanzhou Coal Mining up 10.01%, and China Shenhua Energy also seeing gains [1] Group 2 - The Shanghai 180 ETF index fund (530280) has seen a net value increase of 14.84% over the past six months, with a maximum monthly return of 9.13% since inception [2] - The fund has a historical average monthly return of 3.08% and a 100% probability of profitability over one year, with a Sharpe ratio of 2.08 as of January 30, 2026 [2] - The fund's maximum drawdown this year is 4.28%, with a management fee of 0.15% and a custody fee of 0.05% [2] Group 3 - As of January 30, 2026, the top ten weighted stocks in the Shanghai 180 Index include Zijin Mining, Kweichow Moutai, China Ping An, and others, collectively accounting for 24.85% of the index [3] - The individual weightings of these stocks vary, with Kweichow Moutai at 4.22% and China Ping An at 2.87% [4]

Strategy Research - The macroeconomic landscape shows a divergence in performance, with strong demand for technology hardware driven by AI infrastructure investment, while chemical prices remain robust due to supply constraints [2][3] - High-end liquor prices are stabilizing, indicating some recovery in consumer spending, although the sustainability of this trend remains uncertain [3][4] Food and Beverage Research - The company Sobo Protein is expected to maintain rapid profit growth in Q4 2025, with projected net profit for 2025 ranging from 178 to 191 million yuan, reflecting a year-on-year increase of 46.89% to 57.62% [8][36] - The company is focusing on high-end manufacturing and energy optimization, which is expected to enhance profitability [37] Automotive Research - The Robotaxi market in China is projected to reach a value of 50 billion yuan, with hardware cost reductions and software iterations driving demand [11][29] - The commercial viability of Robotaxi is approaching a critical point, with both L2 and L4 participants accelerating market penetration [11][29] Consumer Sector - The price of high-end liquor, such as Moutai, has increased by 3.9% for original and 3.0% for bulk, likely due to pre-holiday gifting demand [4][16] - The real estate market remains weak, with significant declines in transaction volumes across major cities, although policies to stabilize the market are being implemented [4][16] Technology and Manufacturing - The price of DRAM storage has shown signs of stabilization, with a slight decrease in DDR4 prices and a slight increase in DDR5 prices, while overall prices remain high [5][17] - Chemical prices continue to be strong, with PX prices increasing by 5.2% [5][17] Logistics and Transportation - Passenger transport demand remains stable ahead of the holiday season, with a slight increase in logistics demand reflected in highway and rail freight volumes [18] - Shipping rates have shown mixed trends, with domestic port throughput increasing, indicating a potential recovery in export activity [18] Industry Tracking: Machinery - The company Hangzhou Steam Turbine has signed its first commercial contract for a self-developed gas turbine, marking a significant step towards industrial application [19][20] - The company is also advancing its "B to A" strategy to enhance financing channels for high-investment R&D projects [21] Industry Research: Pharmaceuticals - The total market value of publicly held pharmaceutical stocks decreased from 397.7 billion to 316.1 billion yuan, indicating a decline in investor confidence [23][24] - The chemical preparation sector remains the largest segment within pharmaceutical holdings, accounting for 37.5% of total holdings [23] Industry Research: Information Technology - The median profit growth for computer companies is significantly higher than revenue growth, indicating a trend of improving profitability despite stagnant sales [25][26] - A notable number of companies are experiencing significant profit declines, highlighting a polarized performance within the sector [26][28]

港股一日游，低开低走后一路回撤，截至物品下跌0.61%。恒生互联网跌幅居前，恒生科技、恒生医疗等紧随其后，恒生银行逆势小涨。 恒生医疗低开低走，截至目前下跌2.12%，直逼前期低点。其中石油集团大跌2.83%，康方生物下跌2.48%，中国生物下跌2.37%，药明生物、药明康德、 翰森制药等多股跌幅均在2%上方。 恒生银行冲高回落，盘中一度上涨1.03%，截至目前上涨0.34%。其中青岛银行大涨4.78%，交通银行上涨2.25%，中国银行、重庆农村商业银行等股涨幅 均在1%上方；郑州银行、渣打银行、汇丰控股等均小幅下跌。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ 恒生互联网低开低走，截至目前大跌3.08%。其中商汤大跌3.73%，腾讯控股下跌3.7%，百度集团、地平线机器人、百度集团、快手、小米集团等超10只 个股跌幅在2%上方。 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, indicating a positive outlook based on ongoing technological innovation and demand growth [5][6]. Core Insights - The total market value of pharmaceutical stocks held by public funds decreased from 397.7 billion to 316.1 billion yuan, reflecting a decline of 2.58% from Q3 2025 to Q4 2025. The proportion of pharmaceutical stocks in all public fund holdings fell to 7.95%, down 2.58 percentage points from the previous quarter [6][9]. - The highest proportion of holdings in the pharmaceutical sector is in chemical preparations, other biological products, and medical research outsourcing, which accounted for 37.5%, 20.9%, and 16.4% of the total holdings, respectively [6][13]. - The top five pharmaceutical stocks by market value held by public funds in Q4 2025 were: Heng Rui Medicine (32 billion), WuXi AppTec (30.6 billion), Innovent Biologics (16.7 billion), Mindray Medical (15.2 billion), and CanSino Biologics (10.8 billion) [6][24]. Summary by Sections 1. Pharmaceutical Holdings Proportion - The proportion of pharmaceutical stocks held by public funds decreased to 7.95% in Q4 2025, down from Q3 2025, with a notable decline in non-pharmaceutical public fund holdings [9][10]. 2. Market Value of Pharmaceutical Sub-sectors - In Q4 2025, the market value of pharmaceutical sub-sectors held by public funds was as follows: 1. Chemical preparations: 118.6 billion yuan (37.5%) 2. Other biological products: 66 billion yuan (20.1%) 3. Medical research outsourcing: 51.7 billion yuan (16.4%) 4. Medical devices: 33.3 billion yuan (10.5%) 5. Medical consumables: 9.8 billion yuan (3.1%) [13][12]. 3. Public Fund Heavy Holdings - The number of public funds holding the top five pharmaceutical stocks in Q4 2025 was as follows: Heng Rui Medicine (507 funds), WuXi AppTec (448 funds), Mindray Medical (204 funds), Innovent Biologics (202 funds), and BeiGene (162 funds) [17][21]. - The market value growth of public fund heavy holdings in Q4 2025 saw significant increases for Heng Rui Medicine (+20.1 billion), WuXi AppTec (+5.7 billion), China National Pharmaceutical Group (+5 billion), Yingke Medical (+2.2 billion), and Yuyue Medical (+1.8 billion) [28].

Core Insights - The article discusses the growing attention on synthetic lethality as a precise treatment strategy in cancer therapy, targeting tumor-specific gene dependencies to overcome treatment resistance and "undruggable" targets [1][2]. Group 1: Synthetic Lethality Mechanism - Synthetic lethality is based on specific gene combinations where the inactivation of either gene alone does not affect cell viability, but simultaneous inactivation leads to cell death [2][16]. - A classic example of synthetic lethality is the use of PARP inhibitors, which target cancer cells with BRCA1 or BRCA2 mutations, leading to cell death due to the inability to repair DNA damage [3][18]. - Since the approval of the first PARP inhibitor, olaparib, in 2014, several others have emerged, showing efficacy in ovarian, breast, prostate, and pancreatic cancers [19]. Group 2: New Combinations and Research - The success of PARP inhibitors has encouraged further exploration of other "golden combinations" in synthetic lethality, such as MSI-WRN in colorectal and endometrial cancers, where inhibiting WRN can selectively kill cancer cells [4][20]. - Another promising combination is MTAP-PRMT5, where the loss of MTAP in melanoma and mesothelioma leads to a dependency on PRMT5, with inhibitors currently in clinical trials [6][22]. - Over 30 candidate drugs based on synthetic lethality mechanisms are currently in clinical development, focusing on key pathways like DNA damage repair, RNA splicing, and cell cycle regulation [6][22]. Group 3: Challenges in Development - Despite the potential of synthetic lethality, challenges remain in translating laboratory findings into effective drugs for patients, particularly due to the complexity of gene interactions [7][23]. - Many synthetic lethality combinations involve homologous genes, which can lead to toxicity when targeting similar genes, necessitating precise drug design [10][25]. - The applicability of identified synthetic lethality combinations can vary across different cancer types, requiring ongoing research to validate and assess their effectiveness [10][25]. Group 4: WuXi Biology's Role - WuXi Biology provides comprehensive biological services and solutions to support the early development of synthetic lethality drugs, from target discovery to candidate screening and clinical trials [11][26]. - The platform offers various in vitro testing tools and has established nearly 40 animal models related to BRCA deficiencies, covering multiple cancer types for in vivo research [12][27]. - WuXi Biology has developed around 50 animal models for PRMT5 and WRN pathways, supporting the development and evaluation of new synthetic lethality therapies [14][29].